In conclusion, our work showed effectiveness in treating obesity-associated diabetes as well as protective effect against CVD as shown by the AIP, which might be partly due to the attenuation of inflammatory mediators, TNF-α and IL-6. This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.